Daunorubicin liposome
For patient information regarding Daunorubicin liposome, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Steven Bellm, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.Black Box Warning
|
WARNINGS
See full prescribing information for complete Boxed Warning.
* Cardiac function should be monitored regularly in patients receiving DaunoXome (daunorubicin citrate liposome injection) because of the potential risk for cardiac toxicity and congestive heart failure. Cardiac monitoring is advised especially in those patients who have received prior anthracyclines or who have pre-existing cardiac disease or who have had prior radiotherapy encompassing the heart.
|
Overview
Daunorubicin liposome is an anthracycline that is FDA approved for the treatment of advanced HIV-associated Kaposi's sarcoma. There is a Black Box Warning for this drug as shown here. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
{{{fdaLIADAdult}}}
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Daunorubicin liposome in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Daunorubicin liposome in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
{{{fdaLIADPed}}}
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Daunorubicin liposome in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Daunorubicin liposome in pediatric patients.
Contraindications
{{{contraindications}}}
Warnings
{{{warnings}}}
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trials Experience of Daunorubicin liposome in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Daunorubicin liposome in the drug label.
Drug Interactions
{{{drugInteractions}}}
Use in Specific Populations
Pregnancy
{{{useInPregnancyFDA}}}
Labor and Delivery
There is no FDA guidance on the use of Daunorubicin liposome during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Daunorubicin liposome with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Daunorubicin liposome with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Daunorubicin liposome with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Daunorubicin liposome with respect to specific gender populations.
Race
There is no FDA guidance on the use of Daunorubicin liposome with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Daunorubicin liposome in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Daunorubicin liposome in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Daunorubicin liposome in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance on the use of Daunorubicin liposome in patients who are immunocompromised.
Administration and Monitoring
Administration
{{{administration}}}
Monitoring
There is limited information regarding Monitoring of Daunorubicin liposome in the drug label.
Overdosage
{{{overdose}}}
Pharmacology
{{{drugBox}}}
Mechanism of Action
{{{mechAction}}}
Structure
{{{structure}}}
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Daunorubicin liposome in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Daunorubicin liposome in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Daunorubicin liposome in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Daunorubicin liposome in the drug label.
How Supplied
{{{howSupplied}}}
Images
Package and Label Display Panel
{{{packLabel}}}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Daunorubicin liposome in the drug label.
Precautions with Alcohol
Alcohol-Daunorubicin liposome interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
®
Look-Alike Drug Names
A® — B®
Drug Shortage Status
References
The contents of this FDA label are provided by the National Library of Medicine.